HIF-2α inhibitors such as PT2385 and belzutifan aim to halt these adaptive responses by preventing HIF-α dimerization with ARNT, while VEGF inhibitors correct tumor oxygenation by suppressing abnormal vascularization [74–76]. Here, EPAS1 is linked to neoplasm.